期刊
BIOLOGY OF THE NEONATE
卷 85, 期 2, 页码 138-144出版社
KARGER
DOI: 10.1159/000074970
关键词
erythropoietin; neuroprotection; blood-brain barrier; pharmacokinetics; spinal fluid
类别
资金
- NCRR NIH HHS [RR00082] Funding Source: Medline
- NIAAA NIH HHS [AA12403] Funding Source: Medline
- NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000082] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012403] Funding Source: NIH RePORTER
Erythropoietin (Epo) decreases neuronal injury and cell death in vitro and in vivo. To lay the groundwork for use of Epo as a potential therapy for brain injury, we tested the hypothesis that systemic dosing of high-dose recombinant Epo (rEpo) would result in neuroprotective rEpo concentrations in the spinal fluid of adult and developing animals. This report characterizes the pharmacokinetics of high-dose rEpo in the blood and spinal fluid of juvenile and adult nonhuman primates (n = 7) and fetal sheep ( n = 37) following a single injection. Timed blood and spinal fluid samples were collected following rEpo injection. Epo accumulation in spinal fluid was dependent on peak serum concentration and time following injection. We demonstrate that high-dose rEpo was well tolerated and results in neuroprotective concentrations in spinal fluid of adult and developing animal models by 2 - 2.5 h after injection. Copyright (C) 2004 S. Karger AG, Basel.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据